APOBEC3B and breast carcinoma: The observation that the APOBEC3B deletion polymorphism does not seem to have any impact on the clinical outcome for breast cancer patients, whereas increased expression of APOBEC3B mRNA does, strengthens the evidence that there are two different molecular mechanisms in place.